Educational information, not medical advice — ask your doctor or midwife.
Track Nicotinamide (Non-Flush B3) with reminders and record whether it helped, in the app.
Nicotinamide (also called niacinamide) is one of the two main forms of vitamin B3, the other being niacin (nicotinic acid). Unlike niacin, nicotinamide does not cause the intense skin flushing and tingling that many people find intolerable, making it a more practical choice for daily supplementation. It is found naturally in food and is also produced in the body from dietary tryptophan.
Nicotinamide is a direct building block for NAD+ (nicotinamide adenine dinucleotide), a molecule that powers energy production in virtually every cell in the body and plays a key role in DNA repair. It also calms overactive inflammatory signals in the skin and joints, and helps insulin work more effectively in cells that manage blood sugar. Topically, it strengthens the skin's protective barrier, reduces pigmentation, and visibly shrinks pores over time.
Oral forms include capsules, tablets, and powder — all similarly absorbed. For skin conditions, topical niacinamide serums (typically 2–10% concentration) are widely used and have strong cosmetic and clinical evidence. Some practitioners use high-dose oral forms specifically for osteoarthritis or blood sugar support under supervision.
B3 deficiency (pellagra) was a major public health crisis in the early 20th century, particularly in the American South and parts of Europe where corn-based diets were common. The discovery that niacin and niacinamide cured pellagra in the 1930s was a landmark moment in nutritional medicine. Since then, nicotinamide's unique non-flush profile has made it the preferred B3 form for therapeutic and cosmetic use.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
Reviewed by the HealisticMD editorial team How we grade evidence →
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.